Spravato vs IV Ketamine: What’s the Difference

If you’re exploring ketamine-based treatments for depression, anxiety, or PTSD, you’ve likely heard about both Spravato and ketamine IV therapy. When you’re struggling with symptoms that haven’t responded to traditional antidepressants, choosing between these two options can feel overwhelming. At Catalyst Health & Wellness, we treat both conditions and understand that Spravato vs ketamine IV represents more than just different delivery methods. Each has distinct advantages, limitations, and patient profiles. This guide breaks down the real differences so you can make an informed decision with your healthcare provider.

What Is Spravato (Esketamine)?

Spravato is the brand name for esketamine, a nasal spray approved by the FDA in 2019 for treatment-resistant depression. Esketamine is one half of the ketamine molecule (specifically, the S-enantiomer, or left-handed version). The FDA approved it because research shows esketamine works more directly on brain receptors linked to mood regulation than standard ketamine formulations. When you use Spravato, the medication bypasses your digestive system and enters the bloodstream through nasal tissue, reaching your brain quickly.

The typical protocol involves two doses per week for the first four weeks, then gradual reductions. You receive treatment in a medical office where you’re monitored for several hours after each session. Unlike ketamine IV therapy, Spravato is approved as a standalone treatment, meaning it can work without an oral antidepressant, though combining it with one may enhance results. To learn more about our Spravato therapy services, contact our team.

What Is Ketamine IV Therapy?

Ketamine IV therapy uses racemic ketamine (the full molecule containing both the S and R enantiomers). The medication dissolves in saline and enters your bloodstream through an IV line, delivering rapid antidepressant effects. IV ketamine has been used in anesthesia for decades, and researchers discovered its rapid antidepressant properties in the early 2000s. Unlike Spravato, ketamine IV is not yet FDA-approved specifically for depression, though it’s used off-label by qualified clinicians across the U.S.

The typical course involves 6 infusions over 2-3 weeks, with each session lasting 40-45 minutes. Response rates range from 35-60% depending on your condition and treatment history. At Catalyst Health & Wellness, our founder Dr. Michael Ho brings 30+ years of ketamine expertise to each patient’s protocol. Learn more about our ketamine therapy options.

Mechanism of Action: How They Actually Work

Both Spravato and ketamine IV work through a similar pathway: blocking NMDA receptors on brain cells, which leads to increased glutamate release and activation of downstream signaling. This mechanism differs fundamentally from traditional antidepressants, which take weeks to work because they adjust serotonin levels. The key mechanistic difference is potency. Esketamine (Spravato) is roughly twice as potent as racemic ketamine at the NMDA receptor and has a fourfold higher affinity than arketamine (the R-enantiomer).

In theory, this means Spravato should achieve its effects at lower doses. In practice, research reveals a more nuanced picture: some studies show racemic ketamine actually produces faster symptom improvement and higher remission rates, possibly because the combined enantiomers engage multiple neural pathways. The research isn’t settled, and both routes show legitimate antidepressant effects.

FDA Status and Regulatory Approval

This is a critical distinction. Spravato is FDA-approved for depression. It received Breakthrough Therapy Designation and was approved in 2019 for adults with treatment-resistant depression. In 2020, the FDA expanded approval to include major depressive disorder with acute suicidal ideation or behavior. Most recently, Spravato gained approval for use as monotherapy (without a required companion antidepressant). This regulatory status means insurers recognize it, clinical protocols are well-established, and its safety profile is formally documented.

Ketamine IV, by contrast, is not FDA-approved for depression. Clinicians prescribe it off-label, which is legal but means you’re using a medication for an indication beyond what the FDA formally approved. Off-label use isn’t inherently inferior. Many psychiatric medications are prescribed this way. However, it does mean less formal regulatory oversight and more variability between clinics.

Administration, Duration, and Office Experience

The patient experience differs significantly between these treatments. With Spravato, you arrive at the clinic, self-administer the nasal spray (under supervision), and remain in the office for observation. Side effects like dissociation typically peak within 30-40 minutes and resolve within 1-2 hours. You need someone to drive you home, as you shouldn’t operate machinery for the rest of the day. Dosing is typically twice weekly for weeks 1-4, then maintenance doses every 1-2 weeks.

With ketamine IV, a nurse inserts an IV line and infuses medication over 40-45 minutes. You sit comfortably in a chair or recline, often with music or a therapist present if you’re doing Ketamine Assisted Psychotherapy (KAP). Dissociation and other effects resolve faster (usually by the end of the session). The infusion schedule is typically 6 sessions over 2-3 weeks, then periodic maintenance. Some patients prefer the IV experience because effects resolve more quickly; others prefer the nasal spray’s shorter office time. Both require a commitment to the full course for optimal results.

Side Effects and Tolerability

Both treatments carry similar short-term risks: dissociation, sedation, dizziness, and nausea. These effects are temporary and resolve within hours. Spravato carries a Boxed Warning regarding sedation, dissociation, and potential for abuse or misuse because it’s a Schedule III controlled substance. The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) program, which mandates office administration and monitoring. Ketamine IV carries similar dissociative effects but no formal REMS program.

Both treatments can cause transient elevation in blood pressure and heart rate. Some patients report difficulty with memory during treatment sessions. This dissociative state is actually considered part of the therapeutic mechanism. Long-term safety data is still emerging for both, though years of clinical use suggest serious adverse effects are rare when administered properly. Serious risks include psychological dependence and abuse potential, which is why both treatments should only be administered by trained clinicians in appropriate settings.

Insurance Coverage and Cost

Spravato’s FDA approval means many insurance plans cover it, particularly if you meet criteria for treatment-resistant depression (failed 2+ oral antidepressants). Coverage varies by plan, deductible, and copay structure. Ketamine IV is rarely covered by insurance because it’s off-label. Most patients pay out of pocket, with costs typically ranging from $400 to $800 per infusion. At Catalyst Health & Wellness, we provide transparent pricing and discuss options during your free consultation. Don’t let cost alone determine your choice. Efficacy and your personal response matter most. Check out our pricing page for current rates and payment options.

Who Should Choose Spravato?

Spravato is ideal if you want FDA-approved, insurance-covered treatment with a well-established clinical protocol. It’s also excellent if you prefer frequent but shorter office visits and if traditional medication side effects concern you. Spravato works well for people with moderate-to-severe depression who haven’t responded to at least two antidepressants. It’s approved for those with acute suicidal thoughts and is available across most major U.S. markets. If you value the formal regulatory structure and extensive clinical data, Spravato provides that foundation. If you’re interested in learning whether Spravato is right for you, explore our depression treatment services.

Who Should Choose Ketamine IV?

Ketamine IV is ideal if you want rapid response with effects that completely resolve by session end. It’s excellent for patients who prefer the IV route or who respond better to the full ketamine molecule (both enantiomers). Ketamine IV may work better for some patients whose depression involves chronic pain, PTSD, or anxiety alongside mood symptoms. It’s also ideal if your condition requires a different treatment philosophy than Spravato. Some clinicians believe racemic ketamine’s dual-enantiomer profile provides advantages. At Catalyst Health & Wellness, we practice Ketamine Assisted Psychotherapy (KAP), which integrates therapy during and after infusions, amplifying lasting psychological healing alongside neurochemical change. Learn more about how we can help with anxiety and PTSD treatment.

Ready to Find Your Path Forward?

The choice between Spravato and ketamine IV isn’t one-size-fits-all. Both treatments offer hope for treatment-resistant depression and other conditions when traditional antidepressants fail. Spravato brings FDA approval and insurance coverage; ketamine IV offers rapid onset and personalized protocols. The best treatment is the one your body responds to and your provider feels confident administering. At Catalyst Health & Wellness in Houston, our team of Dr. Michael Ho, Jennifer Lancaster (LCSW-S), and Linda Barnard (RN, LPC) specializes in both approaches. We combine deep ketamine expertise with compassionate care tailored to your specific needs.

Call us at (713) 772-5315 to schedule your free consultation. Visit us at our Heights location (104 W. 12th Street, Suite B) or Southwest Houston clinic (7710 Beechnut St, #206), or South Loop Location

Email: help@catalystketamine.com

The information on this page is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare provider before beginning any new treatment.